This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Fundació Clínic per a la Recerca Biomèdica | |
|---|---|
| Name | Fundació Clínic per a la Recerca Biomèdica |
| Location | Barcelona, Catalonia, Spain |
| Focus | Biomedical research, Clinical research, Translational medicine |
| Parent organization | Hospital Clínic de Barcelona |
Fundació Clínic per a la Recerca Biomèdica is a Barcelona-based biomedical research foundation linked to Hospital Clínic de Barcelona, active in clinical and translational research across Spain and Europe. It operates within networks that include academic institutions, healthcare organizations, and international research consortia to support biomedical projects, training, and infrastructure. The foundation supports investigators, organizes clinical trials, and coordinates collaborations with regional, national, and international partners in medicine and public health.
The foundation emerged from institutional initiatives associated with Hospital Clínic de Barcelona, with antecedents in collaborations involving Universitat de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, and other Catalan research entities. Early engagements linked the foundation to European frameworks like the Horizon 2020 programme and national initiatives such as projects funded by the Instituto de Salud Carlos III and interactions with Agència de Qualitat i Avaluació Sanitàries de Catalunya. Over time the foundation established formal ties to research infrastructures akin to Barcelona Supercomputing Center partnerships and engaged networks including European Research Council grantees, connecting investigators to networks led by institutions like Institut Pasteur, Massachusetts General Hospital, Johns Hopkins University, and Karolinska Institutet.
The foundation’s mission aligns with mandates common to biomedical organizations affiliated with Hospital Clínic de Barcelona and Universitat de Barcelona: to promote clinical research, accelerate translational pathways, and improve patient outcomes through collaborative science. Objectives include supporting investigator-initiated studies, facilitating multicentre trials modeled on consortia involving World Health Organization recommendations, and fostering training programs comparable to offerings from European Molecular Biology Laboratory and Wellcome Trust-backed initiatives. Strategic aims reference standards set by entities such as European Medicines Agency, Food and Drug Administration, and professional societies like European Society of Cardiology.
Governance reflects hybrid models used by foundations linked to academic hospitals; boards often include representatives from Hospital Clínic de Barcelona, Departament de Salut de la Generalitat de Catalunya, and academic leaders from Universitat de Barcelona. Executive teams operate with roles analogous to chief scientific officers found at CERN-partner institutes and clinical trial units modeled after National Institutes of Health research networks. Advisory committees may include experts with affiliations to World Health Organization, European Commission, European Institute of Innovation and Technology, and regulatory advisors formerly associated with Agència Espanyola de Medicaments y Productos Sanitarios.
Programs emphasize translational medicine across thematic areas that parallel research streams at institutions such as Vall d'Hebron Research Institute, Institut d'Investigacions Biomèdiques de Barcelona, Centro Nacional de Investigaciones Oncológicas, and international counterparts like Imperial College London. Core areas include oncology programs akin to trials at Memorial Sloan Kettering Cancer Center; infectious disease research comparable to activity at London School of Hygiene & Tropical Medicine and Institut Pasteur; cardiovascular research reflective of collaborations with European Society of Cardiology centers; neuroscience projects similar to work at Max Planck Institute for Brain Research; and immunology studies connected to networks including National Cancer Institute. The foundation supports clinical trial management, biobank curation comparable to BBMRI-ERIC, and data science efforts leveraging expertise found at Barcelona Supercomputing Center and ELIXIR nodes.
Partnerships span local partners such as Hospital Clínic de Barcelona, Universitat de Barcelona, VHIR (Vall d'Hebron Institut de Recerca), and regional health authorities, as well as national collaborations with Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red, and FCRI (Fundació Catalana de Recerca i Innovació). International linkages include cooperative projects with European Commission research programmes, consortia involving European Research Council awardees, and institutional collaborations with Harvard Medical School, University of Oxford, University of Cambridge, Karolinska Institutet, University of California, San Francisco, and networks coordinated by World Health Organization branches. Industry partnerships mirror models seen with pharmaceutical firms such as Roche, Novartis, Pfizer, and biotech alliances characteristic of European Federation of Pharmaceutical Industries and Associations collaborations.
Funding sources include competitive grants from Horizon Europe successors, national funding through Instituto de Salud Carlos III, regional support from Generalitat de Catalunya agencies, philanthropic contributions comparable to Wellcome Trust gifts, and industry-sponsored trial contracts similar to agreements with GlaxoSmithKline. Infrastructure resources encompass clinical research units modeled on those at Clinical Trials Units in major hospitals, biobank facilities analogous to BBMRI-ERIC standards, and data platforms influenced by practices at ELIXIR and the Barcelona Supercomputing Center.
The foundation has contributed to multicentre clinical trials, translational discoveries, and capacity building in Catalonia consistent with outcomes reported by partners such as Hospital Clínic de Barcelona, Universitat de Barcelona, Vall d'Hebron Research Institute, and Instituto de Salud Carlos III. Notable outputs include contributions to oncology protocols in collaboration with European Organisation for Research and Treatment of Cancer, infectious disease studies linked to World Health Organization recommendations, and participation in European consortia funded by Horizon 2020 and Horizon Europe. The foundation’s role in nurturing clinician-researchers echoes training models from European Molecular Biology Laboratory and supports research visibility through conferences like European Congress of Clinical Microbiology & Infectious Diseases and European Society of Cardiology meetings.
Category:Medical research foundations in Spain